The text starts here.

News Release

October 9, 2006
For Print (PDF 27KB)

Eisai Receives Decisions of Summary Judgment Motion in
US Legal Action Over Aciphex(R) ANDA Filing

Eisai Co., Ltd.
Eisai Inc.

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that they received the court decisions on October 6, 2006 (The US Eastern time) in response to ANDA-related summary judgment motions for Aciphex(R) (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet(R) ).

The Southern District Court of New York granted the summary judgment regarding the validity of Aciphex(R)'s composition of matter patent in its ruling. The court reserved ruling on the enforceability arguments until after trial. We look forward to a trial and will vigorously defend the Aciphex(R) patent in order to protect our interests.

Aciphex(R) has been shown to have a rapid onset of action and a reliable inhibitory effect on acid secretion related to duodenal ulcers and gastro-esophageal reflux disease, which are confirmed in clinical studies. Aciphex(R) was launched in the U.S. in 1999 and is currently marketed in 79 countries worldwide.

Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120
Cathy Pollini
Corporate Planning and Communications
Eisai Inc.
TEL: +1-201-287-2052